支气管哮喘中核因子κB治疗靶点  

Nuclear factor kappa B as a therapeutic target for bronchial asthma

作　　者：郭琦[1] 周一平[1] 

机构地区：[1]广东医学院附属福田医院呼吸科,深圳518033

出　　处：《国际呼吸杂志》2010年第11期672-675,共4页International Journal of Respiration

摘　　要：转录因子可能在慢性气道疾病的病理生理中扮演重要角色，并可能是一类新颖的抗炎治疗靶点。核因子κB（nuclearfactorkappaB，NF-κB）可能是支气管哮喘（简称哮喘）发病的关键环节。NF-κB靶点的药理抑制剂和基因沉默均已初显平喘端倪。NF-κB亚单位是动物肺部变态反应性炎症和气道高反应性所必需。亚单位可能是哮喘NF-κB治疗靶点的未来研究重点与希望所在，尤其是c—Rel亚单位。Transcription factors may play a key role in the pathophysiology of chronic airway diseases,and also may be targets for novel anti-inflammatory treatments, Nuclear factor kappa B（NF-κB） may be the key element in the pathogenesis of bronchial asthma（asthma）. A novel clue to treat asthma is emerging due to the application of pharmacological inhibitors and gene silencing targeting NF-κB. Crucial to allergic pulmonary inflammation and airway hyperresponsiveness in animals are NF-κB subunits. Targeting NF-κB subunits may be the pivot and dawn of the investigation in the treatment of asthma in the future,especially c Rel subunit target.

关 键 词：支气管哮喘 治疗靶点 核因子ΚB 亚单位 

分 类 号：R562.25[医药卫生—呼吸系统]